The trajectory of copyright's flagship drug presents a complex case for observers in the drug sector. While initially a tremendous success, producing vast sums, the intellectual property lapse and the subsequent arrival of generic competitors have considerably affected revenue. This raises porn questions about the future viability of similar therap